Response to Carfilzomib Therapy

Slides:

Advertisements

Similar presentations

Change in longest diameter = -19%. Change in sum of perpendicular diameters = -21%

Advertisements

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Patient Outcomes Each patient will be evaluated at up to 4 time points (after 2, 4, 8 and 12 cycles) of therapy. Compared to the patient’s baseline evaluation,

Optimal Use of Newly Approved Agents – Carfilzomib and Pomalidomide Lymphoma-Myeloma Symposium October 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville,

Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.

Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach for Proteasome-Inhibitor Based Therapy in Waldenstrom’s.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.

Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

RECIST Overview.

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

A Phase 2 Study of Single-Agent Brentuximab Vedotin for Front- Line Therapy of Hodgkin Lymphoma in Patients Age 60 Years and Above: Interim Results Yasenchak.

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory.

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

Phase II Study: Pembrolizumab + Pomalidomide/Dexamethasone for Patients With R/R MM New Findings in Hematology: Independent Conference Coverage* of ASH.

Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children.

Volume 164, Issue 6, Pages (December 2000)

ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -

Korde N et al. Proc ASH 2012;Abstract 732.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

Vahdat L et al. Proc SABCS 2012;Abstract P

Mateos MV et al. Proc ASH 2013;Abstract 403.

Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation.

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Attal M et al. Proc ASCO 2010;Abstract 8018.

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria M. Tazdait,

Multiple Myeloma:2013 Update Genomies

Niesvizky R et al. Proc ASH 2010;Abstract 619.

Partial Products.

Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer Charles M. Rudin, MD, PhD,

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Partial Products.

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Effect of intravenous calcium and magnesium versus placebo on response to FOLFOX+bevacizumab in the CONcePT trial Hochster HS,1 Grothey A,2 Shpilsky A3,

Journal of Thoracic Oncology

Biology of Blood and Marrow Transplantation

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Linear correlationa between TMB cutoff for ORb for CR/PR rates and HRc for PFS, and OS depending on TMB for patients treated with anti-PD-1/PD-L1 monotherapy.

Genomic determinants of response to cytotoxic chemotherapy.

(A) Survival curves according to clinical response.

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Survival, subsequent therapies, and response.

STK11/LKB1 comutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant LUAC. A, Objective response rate (RECISTv1.1)

* OS >3yr with No Next Line * * * * *

Presentation transcript:

Response to Carfilzomib Therapy Response category %* All patients (n=257) Patients with baseline PN (n=202) Complete response (CR) 0.4 Very good partial response (VGPR) 5.1 Partial response (PR) 18.7 18.3 Minimal response (MR) 10.1 10 Stable disease (SD) 34.6 28.2 Progressive disease (PD) 26.8 33.1 Not Evaluable by IRC 4.4 5 Overall response rate (ORR) 24.1 23.7 Clinical benefit response (CBR=ORR + MR) 34.2 33.7 *Responses as assessed by the Independent Response Committee (IRC) PN= peripheral neuropathy 985